Dr. Bernd Sundermann joins TCG Lifesciences

Press Release… Dr. Bernd Sundermann joins TCG Lifesciences ~ To be based out of Germany ~ New Delhi/ Germany, April 18: TCG Lifesciences Limited, a leading life sciences contract research services and informatics organization enabling translational medicine approach headquartered in India, today announced the appointment of Dr. Bernd Sundermann as an Associate Vice President, Pre-clinical R&D, for looking after its business interests in Europe and European Union. Dr. Sundermann is a medicinal chemist by training and has more than a decade of experience in the fields of Drug Discovery and Pre-clinical Development and holds more than 75 global patents. TCG Lifesciences is focused on delivering end-to-end solution to the global life sciences industry for the discovery and development of superior drugs. It offers a new paradigm where focused research and development is seamlessly transitioned from bench to bedside and back, with laboratory data easily accessed and managed for critical decision making from one enterprise solution across the product development lifecycle. Speaking on the appointment, Mr. Swapan Bhattacharya, Managing Director, TCG Lifesciences said, “We are pleased to have Dr. Sundermann as a member of our scientific leadership team. Dr. Sundermann’s track record and wide experience in Drug Discovery and Pre-clinical Development will not only help TCG Lifesciences in leveraging his excellent scientific skills but will also help strengthen our base in Europe & EU to serve our clients more effectively.” On his new role, Dr. Bernd Sundermann commented, “I am very excited with the opportunity to work with TCG Lifesciences, which has one of the best client relationships and state-of-art infrastructure in the discovery research services space.” Prior to joining TCG Lifesciences, Dr. Sundermann, was Head of Drug Discovery at Grunenthal GmbH in Aachen, Germany. At Grunenthal he has over the years served in a variety of functions with responsibilities spanning across the drug discovery value chain. With the goal to create first-in-class NCEs Dr. Sundermann has worked continuously on the interfaces with pharmacology, pharmacokinetics and toxicology.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.